Publications by authors named "Reeko Osada"
Diagnosis and treatment of pulmonary hypertension (PH) in patients with lung diseases (PH-LD) remain unestablished and pose significant challenges. In this report, we present a case of a 77-year-old patient with an indeterminate for usual interstitial pneumonia pattern along with chronic obstructive pulmonary disease, who developed groups 1 and 3 PH. Following diagnosis, upfront triple oral combination therapy (UTOCT) with macitentan, sildenafil, and selexipag was initiated.
View Article and Find Full Text PDFArticle Synopsis
- * A 74-year-old Japanese woman with a long history of sinus issues and asthma developed AERD after an adverse reaction to NSAIDs, leading to a diagnosis of severe eosinophilic CRSwNP.
- * Switching her treatment from benralizumab to tezepelumab resulted in significant improvements in her asthma symptoms, nasal congestion, and olfactory dysfunction, indicating the importance of tailored therapies for CRSwNP and AERD.
Article Synopsis
- Monosodium glutamate (MSG) is a common food additive known for enhancing flavor, especially in Asian dishes.
- A case report discusses a 21-year-old woman who experienced tongue swelling after consuming snacks, leading to the discovery of a weak allergic reaction to MSG through skin tests.
- An oral challenge test confirmed her allergy with pathology findings showing swelling and mast cell infiltration, marking it as the first documented case of a type 1 allergy to MSG.
Treating ocular involvement in eosinophilic granulomatosis with polyangiitis (EGPA) can be challenging. We present the case of a 37-year-old woman with EGPA who had severe bilateral visual field defects. Laboratory results showed leukocytosis (17,500 WBC/μL, 25.
View Article and Find Full Text PDFArticle Synopsis
- Dupilumab blocks the IL-4/IL-13 pathway, leading to increased eosinophils in the blood, which can potentially contribute to chronic eosinophilic pneumonia (CEP) but no direct link has been established.
- A 33-year-old woman with a history of asthma and previous CEP experienced multiple asthma exacerbations and a recurrence of CEP despite steroid treatment.
- After starting dupilumab, her asthma symptoms improved significantly, and she didn't experience any further asthma exacerbations or CEP relapses over a 12-month period, suggesting it may be an effective option for similar patients.
Introduction: Many studies have reported a poor prognosis for eosinophilic granulomatosis with polyangiitis (EGPA) patients with cardiac involvement.
Case Study: A woman developed EGPA at 37 years of age, with weight loss, numbness in the right upper and lower extremities, muscle weakness, skin rash, abdominal pain, chest pain, an increased peripheral blood eosinophil count (4165/µL), and necrotizing vasculitis on peroneal nerve biopsy. The patient was treated with prednisolone, immunosuppressants, intravenous immune globulin, and mepolizumab, but she experienced many relapses, with chest pain, abdominal pain, numbness, and paralysis, over a long period.
Background: The mainstay of treatment for eosinophilic granulomatosis with polyangiitis (EGPA) is systemic corticosteroid therapy; some patients also receive intravenous immunoglobulins, other immunosuppressive agents, and biologics. Mepolizumab, an anti-interleukin-5 monoclonal antibody, induces remission and decreases the daily corticosteroid dose; however, the clinical efficacy of mepolizumab in EGPA and the prognosis with long-term treatment with this drug are unknown.
Methods: Seventy-one EGPA patients were treated at Hiratsuka City Hospital, Japan, between April 2018 and March 2022.